PD1-Vaxx hasn't even commenced Ph2 clinical trial so I'm not sure what "deal" you are expecting, it isn't like CF33 which has demonstrated exceptional safety profile and excellent efficacy early in Ph1 clinical trial for the massive solid cancer market. Another misleading "information" posted by you and apparently some posters think PH blocked a deal for HER-Vaxx 3 years ago even before the completion of Ph2 clinical trial with very good final result which was only released early last year so clearly PH want to optimise the buy out of HER-Vaxx by selling all the IP and need to get them all to a development stage for a T/O instead of selling HER-Vaxx cheaply and use the funds for development of the other IP.
Add to My Watchlist
What is My Watchlist?
